Common questions about Deliproct (FAQ)
Q: How quickly should I expect to feel a difference after starting Deliproct?
Official product documentation describes the local anesthetic component in Deliproct, known as cinchocaine, as providing quick relief from painful and itching symptoms. This part of the medication is designed to act fast to help manage acute discomfort in the area of application.
Q: How long does the effect of a Deliproct suppository typically last?
Regulatory guidance defines the treatment schedule needed to maintain the therapeutic effect. Official dosing guidelines generally recommend applying the product typically twice daily, once in the morning and once in the evening, after the initial high-frequency phase. This schedule indicates the frequency of application required to support a sustained therapeutic effect.
Q: Are there any specific safety warnings about using Deliproct with other topical creams?
Regulatory safety information notes that certain ingredients (excipients) in the Deliproct ointment may reduce the effectiveness of latex products, such as condoms. Official guidance notes that if an existing skin infection is present, co-administration with appropriate agents, such as topical antibiotics or antifungals, is defined as necessary.
Q: Can Deliproct be used by people who have diabetes?
Official interaction statements indicate that the corticosteroid component of Deliproct has the potential to slightly increase blood glucose concentrations. This effect is documented to reduce the therapeutic effect of medicines used to manage diabetes, such as insulin or oral anti-diabetic agents. This potential interaction necessitates that co-treatment is assessed by a healthcare provider.
Q: Can Deliproct cause changes in skin appearance with prolonged use, based on regulatory filings?
Official product labeling documents risks associated with the prolonged or extensive use of the corticosteroid component. Adverse effects such as skin atrophy (skin thinning) and telangiectasia (the appearance of spider veins) are documented in these regulatory filings. Due to these risks, official guidance states that use is generally limited to short-term durations.
Q: Is Deliproct the same as other hemorrhoid creams or suppositories?
Deliproct is classified as a fixed-dose combination product, which distinguishes it from medicines that contain only a single active ingredient. It merges a potent local anesthetic (cinchocaine) for fast pain relief and an anti-inflammatory corticosteroid (prednisolone acetate) for reducing swelling and inflammation.
Q: Is it normal to feel a mild burning sensation when applying Deliproct for the first time?
Yes, regulatory product labeling reports that local burning and application-site irritation are Common side effects, meaning they may be experienced by up to 1 in 10 people who use the product. If discomfort persists or becomes severe, official guidance notes that the condition should be reassessed.
Q: Is there any research looking at Deliproct use in older adults?
Research documents indicate that clinical investigations exploring the use of this specific combination product in certain patient groups, including older adults, is limited in the published record. The available research generally focuses on the adult population, and findings provide context but not individual predictions.
Q: Is Deliproct associated with any long-term safety concerns mentioned in official sources?
Serious systemic reactions related to the corticosteroid component are documented risks primarily associated with prolonged and/or extensive use. These include the possibility of Adrenal suppression (HPA axis suppression) and clinical manifestations of Cushing's syndrome. For this reason, the official treatment duration is restricted to short-term use.
Q: What should I do if I accidentally swallow a small amount of the Deliproct ointment?
The patient information leaflet states that in the event of accidental ingestion of the ointment or suppositories, urgent medical attention should be sought. This measure is noted to ensure proper medical assessment and guidance can be provided based on the amount ingested and any symptoms.
Q: Are there any official reports of Deliproct interacting with blood thinners?
Yes, official interaction statements indicate that the corticosteroid component may have a variable effect on Vitamin K Antagonists, a class of oral blood thinners. Official documents state that co-treatment may affect the blood thinner's action, which typically necessitates monitoring of coagulation indices.
Q: How long after the expiry date should Deliproct definitely not be used?
Regulatory instructions for pharmaceutical waste are clear that expired medicine must be disposed of according to local regulations. Official regulatory information states that the medicine is not authorized for use past the expiry date printed on its packaging, as the integrity and stability of the product may be compromised.
Q: Why are there warnings about using Deliproct near the eyes?
Warnings are generally related to the corticosteroid component, as both systemic and topical use has been associated with reports of visual disturbance. If any visual issues occur while using this medicine, such as blurred vision, official documentation describes the need for specialized evaluation.
Q: How does Deliproct compare to a product that only contains an anesthetic ingredient?
Deliproct is officially categorized as a combination product intended to provide two simultaneous actions. It combines the fast-acting pain relief from a local anesthetic with a corticosteroid to address underlying inflammation and swelling, offering a dual-mechanism approach to symptomatic management.
Q: Why is it important to use only a small amount of the Deliproct ointment?
The application of unusually large quantities of the topical corticosteroid is associated with an increased risk of absorption of the active ingredients. This higher absorption can lead to a greater risk of experiencing systemic side-effects, which affect the body beyond the application site.
